vs
Side-by-side financial comparison of Atlanta Braves Holdings, Inc. (BATRA) and BillionToOne, Inc. (BLLN). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $61.3M, roughly 1.4× Atlanta Braves Holdings, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -67.6%, a 74.5% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 17.6%).
Atlanta Braves Holdings, Inc. is a sports and entertainment holding company that owns and operates the Atlanta Braves MLB franchise. It also manages adjacent mixed-use real estate, live events, merchandise sales, and media operations, serving fans across the U.S. Southeast and global baseball audiences.
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
BATRA vs BLLN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $61.3M | $83.5M |
| Net Profit | $-41.4M | $5.7M |
| Gross Margin | — | 69.9% |
| Operating Margin | -81.2% | 11.5% |
| Net Margin | -67.6% | 6.8% |
| Revenue YoY | 17.6% | 117.4% |
| Net Profit YoY | -116.7% | 138.3% |
| EPS (diluted) | $-0.64 | $0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $61.3M | — | ||
| Q3 25 | $311.5M | $83.5M | ||
| Q2 25 | $312.4M | — | ||
| Q1 25 | $47.2M | — | ||
| Q4 24 | $52.1M | — | ||
| Q3 24 | $290.7M | $38.4M | ||
| Q2 24 | $282.9M | — | ||
| Q3 23 | $271.8M | — |
| Q4 25 | $-41.4M | — | ||
| Q3 25 | $30.0M | $5.7M | ||
| Q2 25 | $29.5M | — | ||
| Q1 25 | $-41.4M | — | ||
| Q4 24 | $-19.1M | — | ||
| Q3 24 | $10.0M | $-14.9M | ||
| Q2 24 | $29.1M | — | ||
| Q3 23 | $-6.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 69.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 52.6% | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | -81.2% | — | ||
| Q3 25 | 12.5% | 11.5% | ||
| Q2 25 | 13.4% | — | ||
| Q1 25 | -94.2% | — | ||
| Q4 24 | -35.8% | — | ||
| Q3 24 | 2.2% | -32.9% | ||
| Q2 24 | 8.8% | — | ||
| Q3 23 | 5.8% | — |
| Q4 25 | -67.6% | — | ||
| Q3 25 | 9.6% | 6.8% | ||
| Q2 25 | 9.4% | — | ||
| Q1 25 | -87.7% | — | ||
| Q4 24 | -36.7% | — | ||
| Q3 24 | 3.4% | -38.8% | ||
| Q2 24 | 10.3% | — | ||
| Q3 23 | -2.2% | — |
| Q4 25 | $-0.64 | — | ||
| Q3 25 | $0.47 | $0.10 | ||
| Q2 25 | $0.46 | — | ||
| Q1 25 | $-0.66 | — | ||
| Q4 24 | $-0.29 | — | ||
| Q3 24 | $0.16 | $-1.47 | ||
| Q2 24 | $0.46 | — | ||
| Q3 23 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $99.9M | $195.2M |
| Total DebtLower is stronger | $738.6M | $55.0M |
| Stockholders' EquityBook value | $526.0M | $-239.5M |
| Total Assets | $1.6B | $327.5M |
| Debt / EquityLower = less leverage | 1.40× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $99.9M | — | ||
| Q3 25 | $82.2M | $195.2M | ||
| Q2 25 | $96.2M | — | ||
| Q1 25 | $244.7M | — | ||
| Q4 24 | $110.1M | — | ||
| Q3 24 | $100.9M | — | ||
| Q2 24 | $121.2M | — | ||
| Q3 23 | $106.7M | — |
| Q4 25 | $738.6M | — | ||
| Q3 25 | $759.9M | $55.0M | ||
| Q2 25 | $703.1M | — | ||
| Q1 25 | $699.5M | — | ||
| Q4 24 | $617.1M | — | ||
| Q3 24 | $640.1M | — | ||
| Q2 24 | $600.0M | — | ||
| Q3 23 | $555.3M | — |
| Q4 25 | $526.0M | — | ||
| Q3 25 | $560.3M | $-239.5M | ||
| Q2 25 | $522.8M | — | ||
| Q1 25 | $486.1M | — | ||
| Q4 24 | $524.2M | — | ||
| Q3 24 | $530.4M | $-242.9M | ||
| Q2 24 | $512.7M | — | ||
| Q3 23 | $563.6M | — |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | $327.5M | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.6B | — | ||
| Q3 23 | $1.5B | — |
| Q4 25 | 1.40× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.34× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | 1.18× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 1.17× | — | ||
| Q3 23 | 0.99× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.4M | $13.8M |
| Free Cash FlowOCF − Capex | — | $6.5M |
| FCF MarginFCF / Revenue | — | 7.7% |
| Capex IntensityCapex / Revenue | 0.0% | 8.8% |
| Cash ConversionOCF / Net Profit | — | 2.42× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.4M | — | ||
| Q3 25 | $-88.8M | $13.8M | ||
| Q2 25 | $-8.1M | — | ||
| Q1 25 | $95.8M | — | ||
| Q4 24 | $28.9M | — | ||
| Q3 24 | $-69.0M | — | ||
| Q2 24 | $-34.3M | — | ||
| Q3 23 | $-57.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $6.5M | ||
| Q2 25 | $-82.3M | — | ||
| Q1 25 | $76.3M | — | ||
| Q4 24 | $16.8M | — | ||
| Q3 24 | $-85.5M | — | ||
| Q2 24 | $-64.1M | — | ||
| Q3 23 | $-72.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 7.7% | ||
| Q2 25 | -26.3% | — | ||
| Q1 25 | 161.5% | — | ||
| Q4 24 | 32.3% | — | ||
| Q3 24 | -29.4% | — | ||
| Q2 24 | -22.7% | — | ||
| Q3 23 | -26.8% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 8.8% | ||
| Q2 25 | 23.7% | — | ||
| Q1 25 | 41.3% | — | ||
| Q4 24 | 23.2% | — | ||
| Q3 24 | 5.7% | — | ||
| Q2 24 | 10.5% | — | ||
| Q3 23 | 5.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | -2.96× | 2.42× | ||
| Q2 25 | -0.28× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -6.89× | — | ||
| Q2 24 | -1.18× | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BATRA
| Baseball | $34.8M | 57% |
| Mixed Use Development Segment | $26.5M | 43% |
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
